O-4 - 3-month high-egg vs low-egg RCT in prediabetes-T2D found no HDL-C difference (mean diff +0.02 mmol-L, P=0.38)
Registered RCT (ACTRN12612001266853); the tight CI straddling zero on a pre-specified primary endpoint is the study’s headline null.
Link to originalMethodology
Registered RCT (ACTRN12612001266853): 140 overweight/obese adults with prediabetes or type 2 diabetes randomised to a high-egg diet (2 eggs/day, 6 days/week; ~12 eggs/week) or a low-egg diet (<2 eggs/week) for 3 months, embedded in a weight-maintenance program. Both arms received matched macronutrient advice, with a counselled increase in MUFA/PUFA, so the background diet was equalised across arms (a design choice that can blunt a true egg effect). Unblinded, single-site/single-team (Boden Institute, Sydney). Primary outcome: change in HDL-C from screening to 3 months; secondaries: total cholesterol, LDL-C, triglycerides, glycemic control, and appetite ratings. Funding: Australian Egg Corporation (egg-industry funder — a conflict of interest not captured in the step-1 motivatedness note). Depth-limited: exact per-arm secondary values were not recoverable from the accessible abstract/text.
Link to original
Why this is evidence
H-4 predicts no adverse blood-lipid effect of ~12 eggs/week in prediabetes/T2D (a null is expected); the harm-mechanism member H-33 predicts egg-derived cholesterol is handled more atherogenically in this population, i.e. an adverse lipid shift. A pre-specified null HDL-C is the safe pole’s prediction, not the harm pole’s.